Sinopharm Group Co. Ltd. (SHTDF) Stock Price & Analysis
Sinopharm Group Co. Ltd. (SHTDF) — price $2.10 (+0.96%), as of the Nov 20, 2026 trading session; market cap $6.55B.
Educational signal · not a buy or sell recommendation · How to read this
Sinopharm Group Co. Ltd. · SHTDF
Sinopharm Group Co. Ltd. is a major Chinese healthcare company primarily involved in the wholesale and retail distribution of pharmaceuticals, medical equipment, and health products. It operates through extensive distribution networks, a large retail pharmacy chain, and other business segments including manufacturing and IT development.
Price as of Nov 20, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.10 | |
| Change on the day | +0.96% | |
| Market capitalisation | $6.55B | — |
| Price / earnings (trailing) | 6.38 | |
| Shares traded on the day | 2.0K |
Price & events
Other perspectives
Council score for Sinopharm Group Co. (SHTDF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
2 lenses, 2 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Sinopharm Group Co. (SHTDF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Sinopharm Group Co. Ltd. (SHTDF) is the company analyzed here. It employs 94,910 people. In Q2 FY2026 it reported revenue of CN¥278.94B and net income of CN¥3.36B. The market values it at $6.55B.
What do the latest results show for Sinopharm Group Co. (SHTDF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CN¥278.94B. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CN¥278.94B | CN¥3.36B | CN¥1.09 (diluted) |
| Q4 FY2025 | CN¥284.32B | CN¥3.63B | CN¥1.19 (diluted) |
| Q2 FY2025 | CN¥286.04B | CN¥3.46B | CN¥1.11 (diluted) |
| Q4 FY2024 | CN¥289.78B | CN¥3.35B | CN¥1.07 (diluted) |
What are the financial strengths and risks for Sinopharm Group Co. (SHTDF)?
Short answer · as of
The distress and quality screens read Altman Z 2.15 · Piotroski F 6. Trailing ratios: ROE 8.3% · ROA 1.7% · current ratio 1.40 · earnings yield 15.5% · free-cash-flow yield 41.1%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SHTDF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SHTDF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Sinopharm Group Co. Stock: Key Questions Answered
These answers are editorial: 2 of these 8 answers are drawn from the SHTDF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 6 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is SHTDF a good stock to buy?
Stock Expert AI does not rate SHTDF buy, sell or hold. Sinopharm Group Co. Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SHTDF stock price today?
The last price recorded for Sinopharm Group Co. Ltd. (SHTDF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the implications of Sinopharm Group Co. Ltd.'s OTC Other listing for investors?
Sinopharm Group Co. Ltd.'s listing on the OTC Other tier carries several implications for investors. This tier typically has less stringent disclosure requirements compared to major exchanges like NYSE or NASDAQ, and even higher OTC tiers, leading to an "Unknown" disclosure status for SHTDF.
What strategic partnerships does Sinopharm Group Co. Ltd. have and how do they contribute to its operations?
Sinopharm Group Co. Ltd. has formed a strategic partnership with I-Mab, a collaboration designed to enhance its commercial reach and market transformation efforts.
What are the key factors to evaluate for SHTDF?
Evaluate SHTDF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Enhanced Pharmaceutical Distribution and Logistics: The company's core Pharmaceutical Distribution unit, which supplies hospitals, clinics, and other distributors, can capitalize on the increasing volume and complexity of pharmaceutical products entering the Chinese market. Not financial advice.
How frequently does SHTDF data refresh on this page?
SHTDF's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SHTDF's recent stock price performance?
Sinopharm Group Co. Ltd. (SHTDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established and dominant market position within the Chinese healthcare sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SHTDF overvalued or undervalued right now?
The trailing P/E of Sinopharm Group Co. Ltd. (SHTDF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 9 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com